African American relapsed/refractory multiple myeloma patients have a progression free survival benefit with selinexor treatment in the STORM study

被引：0
|
作者：
Cole, Craig [1 ]
Opalikhin, Anne [2 ]
McCartney, Matthew [3 ]
Heideman, Caroline [4 ]
Pentapati, Swetha [4 ]
Wang, Ling [5 ]
机构：
[1] Michigan State Univ, Karmanos Canc Inst, E Lansing, MI 48824 USA
[2] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA
[3] Michigan State Univ, Coll Osteopath Med, McLaren Greater Lansing, E Lansing, MI 48824 USA
[4] Michigan State Univ, Karmanos Canc Inst, McLaren Greater Lansing, E Lansing, MI 48824 USA
[5] Michigan State Univ, Coll Human Med, Dept Med, Div Occupat & Environm Med, E Lansing, MI 48824 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-241
引用
收藏
页码：S168 / S169
页数：2
相关论文
共 50 条
  • [1] Selinexor for the treatment of patients with relapsed or refractory multiple myeloma
    Babar, Anum
    Babar, Maham
    Zubair, Hina
    Shahid, Arzu
    Rafique, Sana
    Bano, Maimona
    Waleed, Madeeha Subhan
    Khan, Maimoona
    Inayat, Arslan
    Safi, Danish
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 535 - 546
  • [2] Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Anum, Babar
    Hina, Zubair
    Mainoma, Bano
    Sana, Rafique
    Arzu, Shahid
    Maham, Babar
    Waleed, Madeeha S.
    Arslan, Inayat
    Danish, Safi
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S29 - S29
  • [3] Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary
    Callander, Natalie
    Tuchman, Sascha
    Chen, Christine
    White, Darrell
    Kotb, Rami
    Sutherland, Heather
    Sebag, Michael
    Baljevic, Muhamed
    Bensinger, William
    Leblanc, Richard
    Venner, Chris
    Bahlis, Nizar
    Rossi, Adriana
    Biran, Noa
    Sheehan, Heidi
    Saint-Martin, Jean-Richard
    Van Domelen, Dane
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Lipe, Brea
    EJHAEM, 2021, 2 (01): : 56 - 65
  • [4] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, Meletios
    Sonneveld, Pieter
    Manier, Salomon
    Lam, Annette
    Roccia, Tito
    Schecter, Jordan M.
    Cost, Patricia
    Pacaud, Lida
    Poirier, Abbey
    Tremblay, Gabriel
    Lan, Tommy
    Valluri, Satish
    Kumar, Shaji
    BMC CANCER, 2024, 24 (01)
  • [5] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [6] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    M A Dimopoulos
    M Hussein
    A S Swern
    D Weber
    Leukemia, 2011, 25 : 1620 - 1626
  • [7] Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos, M. A.
    Hussein, M.
    Swern, A. S.
    Weber, D.
    LEUKEMIA, 2011, 25 (10) : 1620 - 1626
  • [8] Selinexor, daratumumab, and dexamethasone in patients with relapsed/refractory multiple myeloma (MM).
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary J.
    Callander, Natalie Scott
    Tuchman, Sascha
    Bahlis, Nizar J.
    White, Darrell
    Chen, Christine
    Baljevic, Muhamed
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Bensinger, William
    Rossi, Adriana C.
    Sheehan, Heidi
    Arazy, Melina
    Kai, Kazuharu
    Lipe, Brea
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Bahlis, Nizar
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea C.
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    Leblanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie Scott
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2019, 134
  • [10] Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study
    Gavriatopoulou, Maria
    Vogl, Dan T.
    Nooka, Ajay
    Dingli, David
    Cole, Craig
    Moreau, Philippe
    Huff, Carol
    Yee, Andrew
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Richardson, Paul G.
    Stewart, Keith
    Chari, Ajai
    Richter, Joshua
    Biran, Noa
    Siegel, David S.
    Liu, Jianjun
    Joshi, Anita
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E117 - E118
12345